Product Information
OXCARBAZEPINE 300 MG/5 ML SUSP is a generic product labeled by Advagen Pharma Ltd., priced at $0.1102 per ML under NDC 72888007414. Its NADAC has been published 104 times since Oct 9, 2024.
FDA first approved this application on Aug 30, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/5mL
Manufacturer
Advagen Pharma Ltd.NDC
72888007414
Classification
Generic
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
OXCARBAZEPINEApproval Type
Generic (ANDA)
FDA Application
ANDA215726FDA Approved
8/30/2022
TE Code
AB
On Market Since
8/31/2022
Pharmacological Classes
Price Statistics
The NADAC for OXCARBAZEPINE 300 MG/5 ML SUSP has been published 104 times since Oct 9, 2024, and over the history we have for it it has declined 59.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1102 per ML |
|---|---|
| All-time high | $0.2704 (Oct 16, 2024) |
| All-time low | $0.1102 (Sep 23, 2026) |
| 52-week high | $0.1664 |
| 52-week low | $0.1102 |
| Median price | $0.1664 |
| Average price | $0.1794 |
| Largest weekly change | -18.4% (Nov 20, 2024) |
| Weeks tracked | 104 |
| Tracking since | Oct 9, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the OXCARBAZEPINE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Advagen Pharma Ltd. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
OXCARBAZEPINE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anti-epileptic Agent class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OXCARBAZEPINE 300 MG/5 ML SUSP?
The current National Average Drug Acquisition Cost (NADAC) for OXCARBAZEPINE 300 MG/5 ML SUSP, manufactured by Advagen Pharma Ltd., is $0.1102 per ML (NDC 72888007414), effective Sep 30, 2026.
How has the price of OXCARBAZEPINE 300 MG/5 ML SUSP changed over time?
Over the history we have for it, the NADAC for OXCARBAZEPINE 300 MG/5 ML SUSP has declined 59.2%. It has been tracked across 104 weekly CMS publications since Oct 9, 2024.
What are the highest and lowest recorded NADAC prices for OXCARBAZEPINE 300 MG/5 ML SUSP?
Since Oct 9, 2024, the NADAC for OXCARBAZEPINE 300 MG/5 ML SUSP has ranged from a low of $0.1102 (Sep 23, 2026) to a high of $0.2704 (Oct 16, 2024), with a median of $0.1664 per ML.
Are there cheaper alternatives to OXCARBAZEPINE 300 MG/5 ML SUSP?
No other NADAC-published product currently shares the active ingredient and strength of OXCARBAZEPINE 300 MG/5 ML SUSP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures OXCARBAZEPINE 300 MG/5 ML SUSP?
OXCARBAZEPINE 300 MG/5 ML SUSP (NDC 72888007414) is labeled by Advagen Pharma Ltd., and CMS classifies it as a generic product.